Anjalee Khemlani is a reporter at Yahoo Finance covering all things business, with a focus on health care. Khemlani has previously worked for a variety of media organizations that include startup digital, legacy daily news, international broadcast and local radio. Her most recent position was as a managing editor of ROI-NJ in New Jersey.
- Yahoo Finance
Moody's says will be 'many years' before big AI impacts are seen in healthcare, pharma
Moody's says pharma and medical device companies are most likely to see the earliest benefits from adopting AI technology.
- Yahoo Finance
UnitedHealth Group top pick despite cyberattack and DOJ setbacks: BofA
UnitedHealth Group's recent cyberattack and DOJ probe are unlikely to be long-term headwinds, according to a BoA analyst.
- Yahoo Finance
UnitedHealth's cyberattack should be a 'wake-up call' for healthcare
UnitedHealth Group faced a cyberattack that froze an important subsidiary in the healthcare ecosystem.
- Yahoo Finance
Communication is key in managing cyberattack: Optum CEO
UnitedHealth Group's Change Healthcare subsidiary is expected to have a "material update" as early as Tuesday following a major ransomware attack that's now on its fifth straight day and stalling care around the country.
- Yahoo Finance
Moderna CEO: 2024 is year of growth, with 2023 transition in rearview
Moderna posted strong results despite investors assuming a loss for the year.
- Yahoo Finance
Novavax resolves Gavi dispute over COVID-19 vaccines
Novavax has resolved a potentially expensive battle with Gavi, opening up a pathway for the company to get out of the red.
- Yahoo Finance
CVS chief medical officer: 'We are not looking to build the entire healthcare delivery ecosystem'
CVS is bullish on its health services outlook, even as the broader industry faces pressure.
- Yahoo Finance
CEO Bertolini: 2024 is the year Oscar will be profitable
Health insurer Oscar Health says it's going to be profitable in 2024.
- Yahoo Finance
GLP-1s: 'We're investing behind this in a big way,' says Amgen CFO
Amgen is focused on price declines while it looks to fill out its portfolio and chase the new obesity market.
- Yahoo Finance
Eli Lilly CFO: Weight-loss drug demand will outstrip GLP-1 supply through 2024
Eli Lilly blew past Wall Street estimates for its latest earnings but faces pressure ahead to deliver strong results for the year.
- Yahoo Finance
The US government has backed 'food as medicine' movement, but does it have staying power?
The US Health Department held a conference to discuss the federal government's efforts to help address food insecurity.
- Yahoo Finance
Seagen acquisition will give Pfizer 'anchor asset' Wall Street desires: Pfizer CEO Bourla
Pfizer beat earnings expectations, but Wall Street is still waiting to see how it pulls out of waning COVID demand and boosts its pipeline with stronger assets to plug a patent cliff at the end of the decade.
- Yahoo Finance
Novo Nordisk earnings: 'I could smile a long time over results like this,' says CFO Knudsen
Novo Nordisk beat Wall Street estimates for 2023, but its 2024 outlook is what investors are keen on watching.
- Yahoo Finance
How a 'complex' Medicare Advantage market left Humana scrambling to start 2024
Humana signaling rough waters ahead after pent-up demand caused the company to realize losses in its Medicare Advantage business in late 2023.
- Yahoo Finance
Why Wall Street no longer fears sprawling impact from the weight loss drug craze
Obesity drugs, known as GLP-1s, continue to be all the rage in 2024. But doomsday predictions of long-term impact to other industries may be cooling.
- Yahoo Finance Video
Beyond the Ticker: Novo Nordisk
The popularity of Novo Nordisk's (NVO) blockbuster obesity drug Wegovy, and diabetes drug Ozempic, for weight loss, was so great in 2023 that it has been credited with propping up the entire economy of Denmark. It is that impact and buzz that led Yahoo Finance to name Novo Nordisk its 2023 Company of the Year. Novo's gross profit in 2023 was nearly $26 billion, or almost a 27% increase year-over-year. And the stock is on a tear, up more than 50% in the past year. Let’s look at what started Novo’s boom with Beyond the Ticker, where we take a closer look at some of the company's biggest moments. 1923 Nordisk Insulinlaboratorium commercialized the production of insulin. 1925 Two employees broke away from Nordisk to form rival Novo Terapeutisk Laboratorium. 1982 Nordisk first established its presence in the United States. 1985 The NovoPen, the first insulin pen device, launched. 1989 Nordisk and Novo merged to become Novo Nordisk A/S, the world's largest producer of insulin. 2017 The FDA approved Ozempic for diabetes. 2021 The FDA approved Ozempic to treat obesity in diabetes patients. The FDA also approved Wegovy for weight loss in obese or overweight adults. These two products launched a new era in GLP-1s, which have been around since 2005. 2020 - present Novo has spent more than $7 billion on diabetes and obesity biotechs, fortifying its lead in the brand new obesity market. From tech giants to retail titans, Beyond the Ticker is a historical series that takes a deep dive into some of Wall Street's trending companies and how they transformed into the financial icons they are today. Check out more of our Beyond the Ticker series, and be sure to tune in to Yahoo Finance. Editor's note: This video was produced by Zach Faulds.
- Yahoo Finance Video
Rightway CEO talks Tyson Foods choosing his startup over CVS
Tyson Foods (TSN) has announced that it will be dropping CVS' Caremark (CVS) as its pharmacy benefits manager and will be switching to Rightway. This is the second Fortune 100 company to drop CVS in the last year. Could shifts like these open up opportunities for smaller pharmacy benefit management companies? Jordan Feldman, Rightway CEO joins Yahoo Finance Live to discuss what makes the company stand out—and what the benefits landscape could look like soon. Feldman believes that what differentiates Rightway from traditional pharmacy benefit manager is its model. Feldman calls the traditional model a “taxi meter approach," with companies benefiting from members spending more on drugs, rather than focusing on customer experience. Feldman highlights Rightway's “pharmacist in the family approach,” that, according to Feldman, allows for greater customer assistance that ideally would ultimately allow members to make the right decision for their needs. “The pharmacy benefits space is at an inflection point,” insists Feldman, who sees sustainability only being possible if members are at the center. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Eyek Ntekim
- Yahoo Finance
Humana stock falls after reporting higher costs, dragging down other Medicare Advantage providers
Humana (HUM) stock tumbled more than 12% on Thursday after the US health insurer reported an increase in older patients seeking care, which would hurt its fourth quarter results.
- Yahoo Finance
JPM's annual healthcare conference: Here's what's next for GLP-1s and the weight loss market
Several big pharma companies are rushing into the GLP-1 obesity space, which currently has two market leaders. How they plan to take some of that market share will be the story of the drug class for 2024.
- Yahoo Finance
Walgreens CEO: 'We don't need to own a health plan in order to create value'
Walgreens CEO Tim Wentworth discussed the focus away from vertical integration at the JPMorgan healthcare conference in San Francisco.